EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT03932721

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose diagnostic
Phase
Phase 4
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
University of Campinas, Brazil (from the registry)
Registry
  • NCT NCT03932721
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03932721. Randomized; single masking; primary purpose diagnostic. Start 2018-10-01 (actual); primary completion 2021-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial
Acronym
EXCEED-BHS3
Condition
Dyslipidemia Associated With Type II Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Condition
Hypertension Arterial
Intervention (Drug)
Evolocumab 140 MG/ML
Lead sponsor
University of Campinas, Brazil (class: other)

Record details

Record id
cardio:ct-nct03932721
Content hash
7980ed1370b3d91b90ebcee7919a649904b67489ca5aeeb741cb0c037ad02977